<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03583294</url>
  </required_header>
  <id_info>
    <org_study_id>2017-32</org_study_id>
    <secondary_id>2017-32</secondary_id>
    <nct_id>NCT03583294</nct_id>
  </id_info>
  <brief_title>A Study on the Uterus, Ovarian and Reproductive Functions According to Conditioning Regimen and Pubertal Status at the Time of Stem Cell Transplantation in a Leukemia Pediatric Population</brief_title>
  <acronym>FERTILEA</acronym>
  <official_title>A Study on the Uterus, Ovarian and Reproductive Functions According to Conditioning Regimen and Pubertal Status at the Time of Stem Cell Transplantation in a Leukemia Pediatric Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The French L.E.A. (Leucémie Enfant et Adolescent) program was implemented to prospectively&#xD;
      evaluate the long-term health status, quality of life and socio-economic status of childhood&#xD;
      acute leukemia (CAL) survivors enrolled in French treatment programs from 1980 to present, in&#xD;
      15 cancer centers. Eligible patients for the study are adult women (≥18 years) from L.E.A.&#xD;
      cohort. Project has been approved by the Scientific Advisory Board and the Steering Committee&#xD;
      of LEA Cohort. MRI uterus anatomy, follicular ovarian reserve and reproductive function will&#xD;
      be assess in 212 adult women who received a hematopoietic stem cell transplantation (HSCT)&#xD;
      for CAL. The investigator's objective is to correlate uterus and ovarian function to the&#xD;
      conditioning regimen received before HSCT (total body irradiation (TBI) or busulfan - based&#xD;
      conditioning) and the pubertal status at the HSCT (before or after puberty).Inclusion period&#xD;
      is planned for 2 years. Four patient groups will be compared:&#xD;
&#xD;
        -  Group 1: HSCT before nine years and after conditioning regimen with TBI (12 Gy)&#xD;
&#xD;
        -  Group 2: HSCT before nine years and after a busulfan-based conditioning regimen&#xD;
&#xD;
        -  Group 3: HSCT after nine years and after conditioning regimen with TBI (12 Gy)&#xD;
&#xD;
        -  Group 4: HSCT after nine years and after a busulfan-based conditioning regimen&#xD;
&#xD;
      Information will be collected during specific medical visit in one of the investigatory&#xD;
      centers. Pelvic MRI and hormonal blood tests will be performed and a medical consultation&#xD;
      with a physician specialized in reproductive medicine and oncofertility will be proposed to&#xD;
      eligible patients. Data assessed for each women are the following:&#xD;
&#xD;
        -  Disease type, age and pubertal status at HSCT, age at evaluation, therapy lines before&#xD;
           and after HSCT, conditioning regimen, relapse after HSCT if applicable. Cumulative doses&#xD;
           of cyclophosphamide, melphalan, busulfan and radiation will be collected from the LEA&#xD;
           database.&#xD;
&#xD;
        -  Gynecological characteristics: spontaneous or induced puberty, spontaneous menstrual&#xD;
           cycles or Hormone Substitutive treatment (HRT) or amenorrhea without HRT; gestity parity&#xD;
           (if pregnancy: spontaneous, after Assisted Reproductive Technologies?), history of&#xD;
           ovarian cryopreservation, was information given (and at what age?) about risk of&#xD;
           premature ovarian failure and about the gyneco-obstetrical impact of conditioning&#xD;
           regimen for HSCT?&#xD;
&#xD;
        -  Ovarian follicular reserve: FSH, LH, estradiol, Anti-Müllerian Hormon (AMH) at the day&#xD;
           2-3 of the cycle or whenever if amenorrhea. Ovarian volume and antral Follicle Count&#xD;
           will be performed with pelvic sonography.&#xD;
&#xD;
        -  Uterine anatomy by MRI, at the end of follicular phase or after estrogen therapy, in&#xD;
           order to measure proliferative endometrium. Anatomical parameters will be compare to&#xD;
           normal measurements of uterus: uterine volume, myometrial, endometrial and junctionnal&#xD;
           zone thickness, cervical length, apparent diffusion coefficient values.&#xD;
&#xD;
        -  Reproductive function: spontaneous pregnancy rate or after ART (IVF, oocyte donation),&#xD;
           term and mode of delivery, health of the child.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterin Anatomy</measure>
    <time_frame>1 day</time_frame>
    <description>Pelvic echography: Quantitative estimation of the residual ovarian reserve with the count of antral follicles and the thickness of the endometrium and ovarian volume&#xD;
Pelvic IRM: the maximum size of functional endometrium in the proliferative phase</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>irradiation regimen before 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>busulfan regimen before 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML before 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>irradiation regimen after 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after conditioning regimen with total body irradation MRI pelvic will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>busulfan regimen after 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Female who received a hematopoietic stem cell transplantation (HSCT) for AML/CML after 9 years old after a busulfan-based conditioning regimen MRI pelvic will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI pelvic</intervention_name>
    <description>Pelvic MRI</description>
    <arm_group_label>busulfan regimen after 9</arm_group_label>
    <arm_group_label>busulfan regimen before 9</arm_group_label>
    <arm_group_label>irradiation regimen after 9</arm_group_label>
    <arm_group_label>irradiation regimen before 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female treated for acute/chronic myeloide leukemia during chidwood and survived from&#xD;
             this desease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female with uneligible MRI exam conditions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EMILIE GARRIDO PRADALIE</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Blandine COURBIERE, MD/PhD</last_name>
    <phone>+33 491383675</phone>
    <email>blandine.courbiere@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blandine Courbiere, MD/PhD</last_name>
      <email>blandine.courdbiere@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

